Literature DB >> 25981314

Minimally-invasive LVAD Implantation: State of the Art.

Jasmin S Hanke, Sebastian V Rojas, Murat Avsar, Axel Haverich, Jan D Schmitto1.   

Abstract

Nowadays, the worldwide number of left ventricular assist devices (LVADs) being implanted per year is higher than the number of cardiac transplantations. The rapid developments in the field of mechanical support are characterized by continuous miniaturization and enhanced performance of the pumps, providing increased device durability and a prolonged survival of the patients. The miniaturization process enabled minimally-invasive implantation methods, which are associated with generally benefitting the overall outcome of patients. Therefore, these new implantation strategies are considered the novel state of the art in LVAD surgery. In this paper we provide a comprehensive review on the existing literature on minimally-invasive techniques with an emphasis on the different implantation approaches and their individual surgical challenges.

Entities:  

Mesh:

Year:  2015        PMID: 25981314      PMCID: PMC4558356          DOI: 10.2174/1573403x1103150514151750

Source DB:  PubMed          Journal:  Curr Cardiol Rev        ISSN: 1573-403X


INTRODUCTION

According to today´s definition, the first left ventricular assist device was implanted minimally-invasively. In July of 1963, Stanley Crawford and Domingo Liotta implanted the first intrathoracic LVAD in a human bypassing the left ventricle from the left atrium to the descending thoracic aorta via left thoracotomy [1-4]. Mankind long dreamed of creating a total artificial heart (TAH) that could replace the failing human heart [5, 6]. Left ventricular assist devices (LVAD) evolved due to further clinical findings on terminal heart failure and its profound impact on the left ventricle, creating another milestone towards the development of the TAH. Three years after the first LVAD implantation in April 1966, DeBakey and Liotta implanted the first clinical LVAD in a paracorporal position, bypassing the left ventricle from the left atrium to the ascending aorta via full sternotomy. In both cases the patients died of perioperative complications [3, 4]. The first successful treatment by a LVAD took place in October 1966 when DeBakey and Liotta implanted a temporary support in a patient in postcardiotomy shock – again via full sternotomy [2-4].Eventually, the first TAH implantation in man was performed by Denton A. Cooley in April of 1969 – two years after Christian Barnard performed the first human heart transplantation and three months before Apollo 11 landed on the moon [5-9]. The following rapid developments in the field of mechanical support are characterized by continuous miniaturization and enhanced performance, providing increased device durability and a prolonged survival of the patients. Yet, despite all mechanical advances, heart transplantation is still the gold standard for the therapy of end stage heart failure [10-13]. However, transplantation is limited by donor shortage, which is causing mortality rates of approximately 30% on the waiting lists. Subsequently, the total amount of transplanted hearts has been continuously decreasing in the past years [14, 15]. Implanting LVADs “off the shelf” is an attractive alternative to transplantation. This applies especially to emergency cases as a bridge-to-transplant, or for patients who do not fulfill the transplantation requirements. Nowadays, the worldwide number of LVADs being implanted per year is higher than the number of cardiac transplantations. LVADs clinical success is based on the shift from pulsatile to continuous flow pumps [16, 17]. With this change in paradigm, the durability of the pumps increased, while simultaneously the size and weight of the devices decreased. This has enabled minimally-invasive surgery for the implantation, explantation and exchange of ventricular assist devices [18-22]. Minimally-invasive cardio surgical procedures are known to be generally associated with many positive effects, e.g. reduction of trauma, blood loss and infection, decrease in intensive care unit and in-hospital stay as well as better outcomes [21-24]. The new developments and implantation techniques of LVADs equally contribute to the improvement of therapy outcomes by reducing important operative complication rates such as right ventricular failure by avoiding pericardial opening [18]. Since the miniaturization process of LVADs steadily continues, it is certainly possible that soon the majority of implantations will be performed using less invasive techniques. This paper reviews the literature on minimal-invasive implantation techniques for the most common adult left ventricular assist devices (HVAD, HeartWare Inc., USA; HeartMate II (HMII), Thoratec Cooperation, USA).

METHOD

A systematic review of the literature was carried out using the Medline database and the search terms “left ventricular assist device”, “LVAD”, “minimal-invasive”, “less-invasive”, “HVAD”, “HeartWare”, “HeartMate II” and “new approach”. The literature search was carried out in October 2014. Only English language papers were incorporated in this review.

DEFINING MINIMAL-INVASIVENESS IN LVAD SURGERY

To this present day there is no common definition of minimal invasiveness existing. In this review, minimally-invasive LVAD surgery is defined as "non-sternotomy approach" which is associated with reduced trauma, thereby representing less invasive surgery compared to the conventional implantation technique via full sternotomy. Yet, miniaturization of the approach in LVAD surgery is limited due to the size of the devices.

CONVENTIONAL LVAD IMPLANTATION TECHNIQUE

The conventional access for LVAD implantation is a full median sternotomy with Heart-Lung-Machine cannulation sites in the ascending aorta and the right atrium (RA). The prominent advantages of this approach are the exemplary anatomical overview and the basic access to the left ventricle (LV). Thus, disadvantages include risks for sternal instabilities and infection as well as postoperative bleedings. It is also prone to secondary right heart failure and especially challenging in re-operative cases [10, 18, 24]. New implantation methods derived from the conventional technique alternating the access paths to pump positioning, outflow graft anastomosis and cannulation site in order to avoid full sternotomy. The major variations will be described in the following passages.

VARIATIONS OF PUMP POSITIONING

The size restraining incision of LVAD implantation is the access path to the left ventricle due to the corpus size of the VADs. Schmitto et al. use an anterolateral thoracotomy to place the sewing ring of the HVAD onto the left ventricle [Figure ]. The pump is inserted and the outflow graft tunneled through the pleural cavity to the ascending aorta. Then, the outflow graft is anastomosed through an upper hemi-sternotomy [18]. The Viennese approach also uses the left lateral mini-thoracotomy to place the HVAD or a left subcostal incision for the placement of the HeartMate II [24]. Popov et al. describe an implantation technique via bilateral anterior thoracotomy incisions [25]. The dominating minimal-invasive technique to implant the corpus of the HeartMate II (HMII) is a left subcostal incision [26]. Due to its size a subcostal pump pocket is needed to fit the pump into the thorax. Gregoric et al. perform a subcostal incision and separate the interfering muscles stopping extraperitoneally above the transverse muscle fascia. Then the pleura is opened in order o allow access to the pericardium and the left ventricular apex below [27]. LVAD exchange is also described via this technique [28]. Anyanwu et al. modified this technique and use it as their routine implantation strategy [29]. Samuels et al. also alternated the approach, combining a left-sided lateral thoracotomy and a partial midline upper abdominal pre-peritoneal laparotomy to form the pump pocket [30].

VARIATIONS OF OUTFLOW GRAFT ANASTOMOSIS

The positioning of the outflow-graft plays an important role in the long term outcome of the patient. False positioning leads to turbulences in the blood flow, resulting in a high risk of outflow graft thrombosis or kinking [31-33]. Schmitto et al. chose an upper mini sternotomy to perform the cannulation and the placement of the outflow graft by tunneling it through the right pleural cavity, leaving the pericardium closed and reducing the risk for right heart failure [18] (Figs. and ). Other approaches avoid sternotomy completely and place the outflow graft to other major arteries. Possible options are the subclavian artery, the innominate artery or the descending aorta. Strueber et al. use a left clavicular incision to suture the outflow graft onto the left sublavian artery [34]. The London Harefield group uses a combination of bilateral anterior thoracotomies to implant the HVAD, using the left subclavian artery for the graft placement [35]. The Viennese group uses a right mini-thoracotomy in the second intercostals space but if additional valve procedures are necessary they switch to mini-sternotomy [24]. Zimpfer et al. described a minimally-invasive HeartMate II implantation in the setting of severe aortic calcification in which the outflow graft is tunneled through the diaphragm, the right thoracic cavity, and the second intercostal space, and is anastomosed to the right subclavian artery [36]. A variation of this approach is the anastomosis of the graft to the bracheocephalical trunk. Endoscopic techniques to suture the outflow graft to the subclavian artery are currently in development to further increase the incision sites. Khalpey et al. introduced the technique of robotic-assisted LVAD implantation after pectoral muscle flap, thereby preserving the flap for transplantation [37]. Less prevalently used than the anastomosis to the ascending aorta is the alternate anastomosis to the descending aorta. Some studies suggest neither outflow-graft location to be inferior to the other. Yet, by the use of this technique the aortic arch remains a region without net flow and is prone to stasis resulting in thrombogenesis [38-40].

VARIATIONS OF CARDIOPULMONARY BYPASS

The conventional cannulation sites for cardiopulmonary bypass (CPB) are the ascending aorta and the right atrium (RA). Variations include the percutaneus or open cannulation of the femoral artery and vein as well as the combination of mini-sternotomy and cannulation of the ascending aorta and the femoral vein [18, 24]. Biventricular cannulation has been described in biventricular assist device implantation [42]. LVAD surgery can also be performed without the use of CPB. The “Off-pump” technique has been described by several groups in device implant, explant and exchange settings [20, 24, 43-50]. Positive assets of the “On-pump” technique are the possibility to inspect the left ventricle (LV) and the superior hemodynamic management options which permits combined cardiac procedures e.g. valve replacements or closing septal defects [24, 41, 51, 52].

VARIATION OF DRIVELINE EXIT SITES

The external driveline is the Achilles` heel of assist devices. It is prone to infection and mechanical stress, causing major complications in VAD therapy [53-56]. The conventional technique is the short and straight driveline tunnel. A modification of this approach is a double subfascial tunneling [57, 58]. Singh et al. describe advantages in externalization of only the silicone portion of the driveline regarding infections [59]. The Hannover group prefers their own double tunnel technique [58] and decides on left or right driveline exit side based on the patients´ history, e.g. sleeping side preferences as well as the handedness of the patient [60].

DISCUSSION

The described minimal-invasive approaches are the novel state of the art in LVAD surgery. Systemic literature review showed, that compared to the conventional approach they are associated with many positive effects, e.g. reduction of trauma, blood loss and infection, decrease in intensive care unit and in-hospital stay as well as better outcomes [19-24]. The new developments and implantation techniques of LVADs contribute to the improvement of therapy outcomes by reducing important operative complication rates such as right ventricular failure by avoiding pericardial opening [18]. Yet, long-term results are still missing. Based on the literature review, the common denominator of the various minimal-invasive implantation techniques is the avoidance of full sternotomy, which represents a common trend in cardiac surgery. Minimal-invasive LVAD implantation is a combination of accessing the apex of the left ventricle via thoracotomy, creating a pump pocket [18, 24-26, 28-30] and a choice of possible outflow graft anastomosis positions [18, 24, 34-37]. The choice of procedure is contingent upon the anatomical situation of the patient. Since the anatomy of re-operative cases is often dominated by adhesions, minimally-invasive techniques offer less traumatic access to the target regions. Furthermore, fewer adhesions are caused, benefitting the anatomical situation in bridge-to-transplant cases [18, 24]. A variation of outflow graft anastomosis positions, to major arteries of the aortic arch or the descending aorta, offer alternative approaches in challenging cases e.g. porcelain aorta [18, 24, 34-37]. Yet, placing the outflow graft to other structures than the ascending aorta may result in flow turbulences or stasis leading to thrombogenesis [38-40]. Robotic-assisted implantation of ventricular assist devices is another step towards further minimizing the surgical trauma of LVAD implantation [37]. Minimal-invasive LVAD implantation may be combined with other procedures e.g. aortic valve repair or closing septal defects [24, 41, 51, 52]. However, the extension of major surgery is limited by the reduced sight and access possibilities and requires highly experienced surgeons. “On-” or “Off-pump” implantation offers another variation of the approach, providing the opportunity to reduce the operating time and the negative effects of the heart-lung-machine [20, 24, 34, 43-48] or increase the hemodynamic safety of the operation and the chance to fully inspect the heart e.g. for ventricular thrombus or perform combined procedures [24, 51, 52]. Recently, on June 25th, 2014, the worldwide first-in-man-Implantation of the novel centrifugal LVAD Heartmate III (Thoratec Corp., Pleasanton, CA, USA) was performed in Hannover, Germany [60]. It is expected to be possibly minimally-invasively impanted soon, too. Despite the many benefits of this method, there is no gold standard in minimally-invasive LVAD surgery as long-term results of the outcomes are still missing. Consequently, the surgeon needs to combine the mentioned implantation strategies to fit individually to the patient in order to guarantee the best results. In summary, minimally-invasive LVAD implantation is the novel state of the art in LVAD surgery due to its association with multiple positive effects compared to the conventional implantation method.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest
Table 1

Overview of Minimal-invasive Left Ventricular Assist Device Implantation techniques

ReferenceDeviceOutflow graft positionPump placement
Schmitto JD [18] J Thorac Cardiovasc Surg. 2012 Heart Ware ”HVAD” Ascending aorta via mini sternotomy Anterolateral thoracotomy
Haberl T [24] Eur J Cardiothorac Surg. 2014 Heart Ware ”HVAD” Ascending aorta via mini sternotomy Left lateral mini-thoracotomy or subcostal incision
Popov AF [25] Ann Thorac Surg. 2012 Heart Ware ”HVAD” Ascending aorta via bilateral thoracotomy Bilateral thoracotomy incisions
Strueber M [34] J Heart Lung Transplant. 2014 Heart Ware ”HVAD” Left subclavian artery Left lateral mini thoracotomy
Hanke JS, Schmitto JD [35] J Thorac Cardiovasc Surg Heart Ware ”HVAD” Innominate artery Anterolateral thoracotomy
Gregoric ID [27] J Heart Lung Transplant. 2008 Thoratec “Heart Mate II” Ascending aorta via mini sternotomy Left subcostal incision and separate the interfering muscles stopping extraperitoneally above the transverse muscle fascia
Anyanwu AC [29] Semin Thorac Cardiovasc Surg. 2011Thoratec “Heart Mate II” Ascending aorta via mini sternotomy Left subcostal incision
Samuels LE [30] J Cardiothorac Surg 2012Thoratec “Heart Mate II” Ascending aorta via mini-sternotomy Left-sided lateral thoracotomy and partial midline upper abdominal pre-peritoneal laparotomy
Riebandt J [36] Ann Thorac Surg. 2013 Thoratec “Heart Mate II” Right subclavian artery Left subcostal incision with preperitoneal creation of the pump pocket
Khalpey Z, Schmitto JD [37] Heart Ware ”HVAD” Robotic anastomosis to the  Ascending aorta Anterolateral thoracotomy
  55 in total

1.  Artificial heart left ventricular assist devices (LVADs): a bridge-to-recovery--the novel LVAD III-intrathoracic small blood pump with atriostomy drainage for combination therapies.

Authors:  Domingo Liotta
Journal:  Ann Thorac Cardiovasc Surg       Date:  2008-10       Impact factor: 1.520

2.  Placement of 2 implantable centrifugal pumps to serve as a total artificial heart after cardiectomy.

Authors:  Martin Strueber; Jan D Schmitto; Ingo Kutschka; Axel Haverich
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02       Impact factor: 5.209

3.  First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III).

Authors:  Jan D Schmitto; Jasmin S Hanke; Sebastian V Rojas; Murat Avsar; Axel Haverich
Journal:  J Heart Lung Transplant       Date:  2015-03-07       Impact factor: 10.247

4.  Off-pump versus on-pump left ventricular assist device exchange.

Authors:  Sebastian V Rojas; Axel Haverich; Jan D Schmitto
Journal:  Artif Organs       Date:  2014-10-20       Impact factor: 3.094

5.  Reduction of driveline infections through doubled driveline tunneling of left ventricular assist devices.

Authors:  Felix Fleissner; Murat Avsar; Doris Malehsa; Martin Strueber; Axel Haverich; Jan D Schmitto
Journal:  Artif Organs       Date:  2013-01       Impact factor: 3.094

6.  Biventricular cannulation is superior regarding hemodynamics and organ recovery in patients on biventricular assist device support.

Authors:  Christian Schlensak; David Schibilsky; Matthias Siepe; Kerstin Brehm; Rolf Klemm; Robert von Wattenwyl; Michael Berchthold-Herz; Christoph Benk; Friedhelm Beyersdorf
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

7.  Orthotopic cardiac prosthesis for two-staged cardiac replacement.

Authors:  D A Cooley; D Liotta; G L Hallman; R D Bloodwell; R D Leachman; J D Milam
Journal:  Am J Cardiol       Date:  1969-11       Impact factor: 2.778

8.  Ventricular assist device in patients with prosthetic heart valves.

Authors:  Suyog A Mokashi; Jan D Schmitto; Lawrence S Lee; James D Rawn; R Morton Bolman; Prem S Shekar; Gregory S Couper; Frederick Y Chen
Journal:  Artif Organs       Date:  2010-11       Impact factor: 3.094

9.  A less invasive approach to axial flow pump insertion.

Authors:  Igor D Gregoric; Saverio La Francesca; Tim Myers; William Cohn; Pranav Loyalka; Biswajit Kar; Courtney Gemmato; O H Frazier
Journal:  J Heart Lung Transplant       Date:  2008-04       Impact factor: 10.247

10.  Left ventricular assist device implantation in high risk destination therapy patients: an alternative surgical approach.

Authors:  Louis E Samuels; Elena Casanova-Ghosh; Roberto Rodriguez; Christopher Droogan
Journal:  J Cardiothorac Surg       Date:  2012-03-12       Impact factor: 1.637

View more
  22 in total

1.  Novel centrifugal pump for heart failure patients: initial success and future challenges.

Authors:  Christina Feldmann; Anamika Chatterjee; Jasmin S Hanke; Guenes Dogan; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  How to do it: tips and tricks of minimal-invasive HVAD® implantation-the lateral approach.

Authors:  Ezin Deniz; Anamika Chatterjee; Christina Feldmann; Jasmin S Hanke; Guenes Dogan; Dominik Berliner; Malakh L Shrestha; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 3.  Pre-transplant ventricular assist device explant.

Authors:  Espeed Khoshbin; Stephan Schueler
Journal:  Ann Cardiothorac Surg       Date:  2018-01

Review 4.  The momentum of HeartMate 3: a novel active magnetically levitated centrifugal left ventricular assist device (LVAD).

Authors:  Anamika Chatterjee; Christina Feldmann; Jasmin S Hanke; Marcel Ricklefs; Malakh Shrestha; Guenes Dogan; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 5.  Effects of pump speed changes on exercise capacity in patients supported with a left ventricular assist device-an overview.

Authors:  Thomas Schmidt; Birna Bjarnason-Wehrens; Sebastian Schulte-Eistrup; Nils Reiss
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 6.  Telemonitoring of left-ventricular assist device patients-current status and future challenges.

Authors:  Nils Reiss; Thomas Schmidt; Michael Boeckelmann; Sebastian Schulte-Eistrup; Jan-Dirk Hoffmann; Christina Feldmann; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

7.  Initial experience with telemonitoring in left ventricular assist device patients.

Authors:  Stephan Hohmann; Christian Veltmann; David Duncker; Thorben König; Dominik Berliner; Jasmin Hanke; Günes Dogan; Anamika Chatterjee; Christina Feldmann; Bryan Lynch; Daniel Burkhoff; Axel Haverich; Johann Bauersachs; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

8.  MitraClip procedure prior to left ventricular assist device implantation.

Authors:  Guenes Dogan; Jasmin S Hanke; Marcel Ricklefs; Anamika Chatterjee; Christina Feldmann; Bakr Mashaqi; Ezin Deniz; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

9.  The influence of less invasive ventricular assist device implantation on renal function.

Authors:  Marcel Ricklefs; Jan Heimeshoff; Jasmin S Hanke; Anamika Chatterjee; Günes Dogan; Malakh Shrestha; Christina Feldmann; Leonhard Wert; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

10.  Left ventricular assist device exchange for the treatment of HeartMate II pump thrombosis.

Authors:  Jasmin S Hanke; Günes Dogan; Leonard Wert; Marcel Ricklefs; Jan Heimeshoff; Anamika Chatterjee; Christina Feldmann; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.